A new Congressional Research Service report finds that US bank policies on cryptocurrency like Bitcoin change frequently depending on who leads regulatory agencies, rather than clear laws. Since 2017, key regulators such as the OCC, Federal Reserve, and FDIC have reversed crypto rules with changes in presidential administrations, creating uncertainty for banks. The report highlights a two-part regulatory test that lacks consensus, causing inconsistent decisions on crypto activities. It suggests Congress could either continue deferring to regulators, pass clear legislation, or adopt a hybrid approach to provide stable guidance for banks dealing with digital assets.
The Congressional Research Service report on US bank policies for Bitcoin provides context for digital asset regulation. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 02, 2026 00:23 WIB: out of 50 major cryptocurrencies, 14 rose and 35 fell. Notable movers include DOT at Rp21.085 with a 1-day change of -6.24%, SUSHI at Rp4.717 down 4.34%, and FIL at Rp18.257 unchanged in buy activity at 100%.
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
RPM International is set to report its Q3 2026 earnings on October 6, with analysts forecasting earnings per share of $1.95 and revenue of $2.22 billion, both higher than the previous year. Despite a slight recent dip in the EPS estimate, the report ...
Jefferies increased its price target for Regeneron to $930, citing an expanded partnership with Sanofi to develop four new long-acting antibodies targeting inflammatory pathways. Sanofi will pay Regeneron $1 billion upfront, with potential milestone ...
McCormick & Company reported fiscal Q3 results with adjusted EPS of $0.86, surpassing estimates of $0.76, and revenue of $2.02 billion, up 17.4% from last year. Growth was driven by the McCormick de Mexico acquisition, pricing actions, and favorable ...
Aehr Test Systems is set to report Q3 earnings of $0.11 per share and revenue around $27 million, marking a 1,000% increase in earnings year-over-year. The company projects fiscal 2027 revenue growth between 160% and 200%, reaching $130-$150 million,...
